It has been demonstrated in vitro and in vivo that SAFB can inhibit TAK1 activity by targeting the first E-box of its promoter, leading to the inhibition of the NF-κB signaling pathway involved in CRC invasion, metastasis, and angiogenesis (Figure 2) [74]. The gene discussed is SAFB; the disease is colorectal carcinoma.